Tocilizumab gives new hope for arthritis patients

 

Clinical trial results described as "striking and exciting" could lead to new treatment options for rheumatoid arthritis.

The antibody drug tocilizumab was almost four times more likely to halt progression of the condition than the most widely prescribed alternative.

It also achieved significantly greater reduction in disease signs and symptoms after six months.

Scientists compared tocilizumab, marketed as RoActemra, with the "anti-TNF" drug adalimumab (Humira).

The drugs were tested in a group of 326 patients unable to take the mainstay treatment for rheumatoid arthritis (RA), methotrexate (MTX)

MTX is ruled out for roughly a third of patients, many of whom suffer unbearable side effects such as vomiting, hair loss and mouth ulcers.

Currently, such individuals generally move onto anti-TNF drugs, which target a molecule called tumour necrosis factor that promotes inflammation.

Tocilizumab works in a completely different way by targeting another inflammatory protein, interleukin six (IL-6).

Consultant rheumatologist Professor Paul Emery, from the University of Leeds, who took part in the Adacta trial, said: "These results are impressive and important for the 30% of patients with RA who cannot take methotrexate.

"In RA, disease remission is the goal of therapy.

"However, for varied reasons, many patients fail to achieve this goal.

"Adacta, which compared two active biologics as monotherapies (in methotrexate intolerant patients), has produced striking results and the results help in choosing the right drug for the right patient."

The findings were presented in Berlin at Eular, the annual meeting of the European Congress of Rheumatology.

Professor John Isaacs, a rheumatology expert from the University of Newcastle, said: "These results are very important and exciting.

"For the tens of thousands of patients in the UK that can't take methotrexate, RoActemra will offer them an increased chance of remission, which is the ultimate goal of rheumatoid arthritis treatment.

"This study is the first time a treatment has gone 'head to head' with an anti-TNF in this setting, and to show a significant increase in patients achieving remission is very impressive."

At £9,500 per patient per year, RoActemra costs about the same as Humira.

The NHS cost-effectiveness watchdog Nice (National Institute for health and Clinical Excellence) has already approved of RoActemra when combined with methotrexate.

The new results may lead to the drug being given to larger numbers of patients on its own.

An estimated 646,000 people in the UK have RA, a painful and disabling condition caused by the immune system attacking the joints.

Of those newly diagnosed, around a half will be unable to work within 10 years.

Ailsa Bosworth, chief executive of the National Rheumatoid Arthritis Society, said: "With any medical condition, remission is the number one target. Curing the person of their illness and enabling them to get on with their life is the ultimate goal.

"For those with rheumatoid arthritis however, there is no cure, they will always have rheumatoid arthritis. Remission for those with RA does not mean the disease has gone, it just means it is better controlled.

"The key to the most successful outcome is an early diagnosis and early treatment with the most effective drug(s)."

PA

PROMOTED VIDEO
Life and Style
ebookNow available in paperback
ebooks
ebookPart of The Independent’s new eBook series The Great Composers
Latest stories from i100
Have you tried new the Independent Digital Edition apps?

ES Rentals

    Independent Dating
    and  

    By clicking 'Search' you
    are agreeing to our
    Terms of Use.

    iJobs Job Widget
    iJobs General

    Tradewind Recruitment: KS2 Teacher

    Negotiable: Tradewind Recruitment: My client is a two form entry primary schoo...

    Tradewind Recruitment: English Teacher

    Negotiable: Tradewind Recruitment: My client is an excellent, large partially ...

    Tradewind Recruitment: Science Teacher

    £90 - £140 per day: Tradewind Recruitment: I am currently working in partnersh...

    Tradewind Recruitment: Year 3 Primary Teacher

    £100 - £150 per day: Tradewind Recruitment: Year 3 Teacher Birmingham Jan 2015...

    Day In a Page

    Isis hostage crisis: The prisoner swap has only one purpose for the militants - recognition its Islamic State exists and that foreign nations acknowledge its power

    Isis hostage crisis

    The prisoner swap has only one purpose for the militants - recognition its Islamic State exists and that foreign nations acknowledge its power, says Robert Fisk
    Missing salvage expert who found $50m of sunken treasure before disappearing, tracked down at last

    The runaway buccaneers and the ship full of gold

    Salvage expert Tommy Thompson found sunken treasure worth millions. Then he vanished... until now
    Homeless Veterans appeal: ‘If you’re hard on the world you are hard on yourself’

    Homeless Veterans appeal: ‘If you’re hard on the world you are hard on yourself’

    Maverick artist Grayson Perry backs our campaign
    Assisted Dying Bill: I want to be able to decide about my own death - I want to have control of my life

    Assisted Dying Bill: 'I want control of my life'

    This week the Assisted Dying Bill is debated in the Lords. Virginia Ironside, who has already made plans for her own self-deliverance, argues that it's time we allowed people a humane, compassionate death
    Move over, kale - cabbage is the new rising star

    Cabbage is king again

    Sophie Morris banishes thoughts of soggy school dinners and turns over a new leaf
    11 best winter skin treats

    Give your moisturiser a helping hand: 11 best winter skin treats

    Get an extra boost of nourishment from one of these hard-working products
    Paul Scholes column: The more Jose Mourinho attempts to influence match officials, the more they are likely to ignore him

    Paul Scholes column

    The more Jose Mourinho attempts to influence match officials, the more they are likely to ignore him
    Frank Warren column: No cigar, but pots of money: here come the Cubans

    Frank Warren's Ringside

    No cigar, but pots of money: here come the Cubans
    Isis hostage crisis: Militant group stands strong as its numerous enemies fail to find a common plan to defeat it

    Isis stands strong as its numerous enemies fail to find a common plan to defeat it

    The jihadis are being squeezed militarily and economically, but there is no sign of an implosion, says Patrick Cockburn
    Virtual reality thrusts viewers into the frontline of global events - and puts film-goers at the heart of the action

    Virtual reality: Seeing is believing

    Virtual reality thrusts viewers into the frontline of global events - and puts film-goers at the heart of the action
    Homeless Veterans appeal: MP says Coalition ‘not doing enough’

    Homeless Veterans appeal

    MP says Coalition ‘not doing enough’ to help
    Larry David, Steve Coogan and other comedians share stories of depression in new documentary

    Comedians share stories of depression

    The director of the new documentary, Kevin Pollak, tells Jessica Barrett how he got them to talk
    Has The Archers lost the plot with it's spicy storylines?

    Has The Archers lost the plot?

    A growing number of listeners are voicing their discontent over the rural soap's spicy storylines; so loudly that even the BBC's director-general seems worried, says Simon Kelner
    English Heritage adds 14 post-war office buildings to its protected lists

    14 office buildings added to protected lists

    Christopher Beanland explores the underrated appeal of these palaces of pen-pushing
    Human skull discovery in Israel proves humans lived side-by-side with Neanderthals

    Human skull discovery in Israel proves humans lived side-by-side with Neanderthals

    Scientists unearthed the cranial fragments from Manot Cave in West Galilee